How to buy AIkido Pharma stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AIkido Pharma stock

Own AIkido Pharma stock in just a few minutes.

AIkido Pharma Inc is a biotechnology business based in the US. AIkido Pharma shares (AIKI) are listed on the NASDAQ and all prices are listed in US Dollars. AIkido Pharma employs 4 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in AIkido Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AIkido Pharma. Find the stock by name or ticker symbol: AIKI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AIkido Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AIkido Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AIkido Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

AIkido Pharma share price

Use our graph to track the performance of AIKI stocks over time.

AIkido Pharma shares at a glance

Information last updated 2021-04-13.
52-week rangeUSD$0.47 - USD$2.55
50-day moving average USD$1.20
200-day moving average USD$0.95
Wall St. target priceUSD$19.00
PE ratio 2.6811
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.97

Buy AIkido Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AIkido Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is AIkido Pharma under- or over-valued?

Valuing AIkido Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AIkido Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AIkido Pharma's P/E ratio

AIkido Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, AIkido Pharma shares trade at around 3x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

AIkido Pharma financials

Revenue TTM USD$9,000
Gross profit TTM USD$9,000
Return on assets TTM -19.59%
Return on equity TTM -61.46%
Profit margin 0%
Book value N/A
Market capitalisation USD$82.9 million

TTM: trailing 12 months

Shorting AIkido Pharma shares

There are currently 2.0 million AIkido Pharma shares held short by investors – that's known as AIkido Pharma's "short interest". This figure is 267.8% up from 542,068 last month.

There are a few different ways that this level of interest in shorting AIkido Pharma shares can be evaluated.

AIkido Pharma's "short interest ratio" (SIR)

AIkido Pharma's "short interest ratio" (SIR) is the quantity of AIkido Pharma shares currently shorted divided by the average quantity of AIkido Pharma shares traded daily (recently around 99.7 million). AIkido Pharma's SIR currently stands at 0.02. In other words for every 100,000 AIkido Pharma shares traded daily on the market, roughly 20 shares are currently held short.

However AIkido Pharma's short interest can also be evaluated against the total number of AIkido Pharma shares, or, against the total number of tradable AIkido Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AIkido Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AIkido Pharma shares in existence, roughly 10 shares are currently held short) or 0.0061% of the tradable shares (for every 100,000 tradable AIkido Pharma shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AIkido Pharma.

Find out more about how you can short AIkido Pharma stock.

AIkido Pharma share dividends

We're not expecting AIkido Pharma to pay a dividend over the next 12 months.

Have AIkido Pharma's shares ever split?

AIkido Pharma's shares were split on a 1113:1000 basis on 27 October 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1113 shares. This wouldn't directly have changed the overall worth of your AIkido Pharma shares – just the quantity. However, indirectly, the new 10.2% lower share price could have impacted the market appetite for AIkido Pharma shares which in turn could have impacted AIkido Pharma's share price.

AIkido Pharma share price volatility

Over the last 12 months, AIkido Pharma's shares have ranged in value from as little as $0.4656 up to $2.55. A popular way to gauge a stock's volatility is its "beta".

AIKI.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AIkido Pharma's is 1.6238. This would suggest that AIkido Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AIkido Pharma overview

AIkido Pharma Inc. , a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site